Lead identification of conformationally restricted ?-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects

Citation

Miriam Carr, Lisa M. Greene, Andrew J.S. Knox, David G Lloyd, Daniela M. Zisterer and Mary J. Meegan, Lead identification of conformationally restricted ?-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects, European Journal of Medicinal Chemistry, 45, 12, 2010, 5752-5766

Abstract

The synthesis and study of the structure-activity relationships of a series of rigid analogues of combretastatin A-4 are described which contain the 1,4-diaryl-2-azetidinone (?-lactam) ring system in place of the usual ethylene bridge present in the natural combretastatin stilbene products. The 1,4-diaryl-2-azetidinones are unsubstituted at C-3, or contain methyl substituent(s) at C-3. The most potent compounds 12d and 12e display antiproliferative activity at nanomolar concentrations when evaluated against the MCF-7 and MDA-MB-231 human breast carcinoma cell lines. 12d exerts antimitotic effects through an inhibition of tubulin polymerisation and subsequent G2/M arrest of the cell cycle in human MDA-MB-231 breast cancer cells, with similar activity to that of CA-4. These novel ?-lactam compounds are identified as potentially useful scaffolds for the further development of antitumour agents which target tubulin.

Description

PUBLISHED

Endorsement

Review

Supplemented By

Referenced By

Sponsor: Higher Education Authority

Sponsor: Science Foundation Ireland

Sponsor: Health Research Board

Sponsor: Enterprise Ireland

Author's Homepage: http://people.tcd.ie/lloyddg
Publisher: Elsevier
Type of material: Journal Article